Bain, RA back InflaRx’s $55M round after early study produces promising results
A little more than a month ago, Germany’s InflaRx rolled out some promising proof-of-concept data from a small Phase IIa study of its lead drug, a complement factor C5a monoclonal antibody targeting a rare skin disease called Hidradenitis Suppurativa.
According to researchers, an impressive 10 of the 12 patients in the study — which included 9 drug-resistant patients — achieved a clinical response, with a significant 50% or greater reduction in inflammatory lesion count (abscesses and inflammatory nodules) and no increase in abscesses or draining fistulas when compared with baseline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
